The insights from SARS-CoV-2 antibody treatment for future emerging infectious diseases

Early treatment with these antibodies can reduce COVID-19-related hospitalisation or death in patients at high risk.1–3 These antibodies can also provide targeted prophylaxis for individuals at high risk, and interrupt transmission of viruses in populations.4 A major concern of SARS-CoV-2 antibodies is the limited commercial value compared with current small-molecule drugs, such as nirmatrelvir plus ritonavir (Paxlovid) and molnupiravir. Small-molecule drugs (typically 0·1–0·6 kilodalton) can penetrate the cell membrane and bind intracellular targets; they are generally more stable than biological drugs and can be administered orally. [...]the target population that would benefit from SARS-CoV-2 antibodies rather than small-molecule drugs needs to be identified. [...]theoretically, inhaling the antibodies might not provide long-lasting exposure in the lungs. [...]the use of the inhalation route for antibodies needs to be explored for its potential value and scenarios for SARS-CoV-2 infection, because it might also be helpful for other infectious diseases.